Despite recent declines, we believe Pfizer stock is a compelling buy right now, with its current price of around $23 likely ...

Pfizer (NYSE:PFE) announced robust sales for the antifungal drug Cresemba in partnership with Basilea Pharmaceutica Ltd, ...

the stock appears undervalued based on its Fair Value estimates, suggesting potential upside for investors. This comprehensive analysis examines Pfizer’s current position, recent performance, and ...

Pfizer halted its oral obesity drug, danuglipron, in April 2025 due to liver injury concerns, a major pipeline setback. Find ...

PFE stock offers high dividend yields supported by cost optimizations and R&D. Discover its potential amid COVID-19 sales ...

Pfizer, currently trading at $23 and maintaining a strong 7.48% dividend yield, has entered into an agreement with 3SBio to acquire a VEGFxPD-1 bispecific, known as SSGJ-707, for an upfront ...

Value investors rely on traditional forms of analysis on key valuation ... value stocks on the market today. One stock to keep an eye on is Pfizer (PFE). PFE is currently sporting a Zacks Rank ...